KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) Accumulated Depreciation & Amortization (2016 - 2025)

AbbVie has reported Accumulated Depreciation & Amortization over the past 14 years, most recently at $7.9 billion for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 10.78% to $7.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.9 billion through Dec 2025, up 10.78% year-over-year, with the annual reading at $7.9 billion for FY2025, 10.78% up from the prior year.
  • Accumulated Depreciation & Amortization was $7.9 billion for Q4 2025 at AbbVie, up from $7.1 billion in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $7.9 billion in Q4 2025 and troughed at $5.6 billion in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $6.6 billion (2023), against an average of $6.7 billion.
  • Year-over-year, Accumulated Depreciation & Amortization increased 0.11% in 2021 and then grew 10.78% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $5.6 billion in 2021, then increased by 7.73% to $6.1 billion in 2022, then grew by 9.83% to $6.6 billion in 2023, then grew by 7.33% to $7.1 billion in 2024, then rose by 10.78% to $7.9 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Accumulated Depreciation & Amortization are $7.9 billion (Q4 2025), $7.1 billion (Q4 2024), and $6.6 billion (Q4 2023).